20
Mylan Laboratories Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is DIFLUNISAL, USP, with a corresponding US DMF Number 28951.
Remarkably, this DMF maintains an Active status since its submission on January 12, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 19, 2015, and payment made on February 26, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II